Pain and Opioids: Integrated Treatment In Veterans

Summary

This trial will recruit veterans with chronic pain (N = 160) who are prescribed buprenorphine for the treatment of opioid use disorder (OUD). We seek to: (1) examine the efficacy of an integrated treatment to reduce pain interference (Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention \[ACT + MBRP\]) compared to an education control (EC) consisting of a protocol-based series of education sessions concerning chronic pain, opioids, and buprenorphine use and (2) examine how theoretically-relevant treatment mechanisms of pain acceptance, engagement in values-based action, and opioid craving are related to treatment outcomes. Interventions will be delivered via the VA Video Connect telehealth modality.

Conditions

• Chronic Pain
• Opioid-use Disorder
• Opioids; Harmful Use

Interventions

BEHAVIORAL

ACT+MBRP

Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.

BEHAVIORAL

Education control

Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• University of Utah

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Duke University

  collaborator OTHER

• Vanderbilt University

  collaborator OTHER

• Biomedical Research Institute of New Mexico

  collaborator OTHER

• Seattle Institute for Biomedical and Clinical Research

  collaborator OTHER

• Queen's University, Belfast

  collaborator OTHER

• University of California, San Francisco

  collaborator OTHER

• San Francisco VA Health Care System

  collaborator FED

• University of New Mexico

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

21 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-07-01

Primary Completion

2025-12-16

Completion

2026-08-31

Countries

• United States

Study Locations